Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Leaps Into Japanese Generics Foray; Aims For 100 Generic Products By 2011

This article was originally published in PharmAsia News

Executive Summary

Pfizer's Established Products Business Unit, a branch in charge of invigorating off-patent drugs and leading generic drug activities, will establish commercial operations in Japan starting Dec. 1

You may also be interested in...



Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma

TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines

Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma

TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines

Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers

Following Pfizer's step, Daiichi Sankyo is venturing into the generic drug business in Japan. The third-largest domestic branded drug maker Feb. 26 announced the establishment of generic subsidiary Daiichi Sankyo Espha, and a plan to start marketing products beginning in October. The announcement has stirred up a shock wave across the industry

Related Content

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel